Genetic testing company 23andMe rises in first trade after Richard Branson SPAC merger
Publishing timestamp: 2021-06-17 16:47:59
Summary
23andMe, a genetic testing company, went public through a merger with Richard Branson's SPAC. The company aims to build a big consumer business and drug research platform. Despite facing challenges, including FDA scrutiny and questions about consumer privacy, 23andMe sees big potential in both its consumer and drug research platforms. The company's founder, Anne Wojcicki, believes that consumers want to use genetic information to change their lives and contribute to drug discovery.
Sentiment: MIXED
Tickers: ME,
Keywords: genetic testing, technology, genetics research, business news, 23andme holding co., genetics, health care industry, health,